Skip to main content
Signal8
Launch Terminal

Obsidian Therapeutics, Inc. (OBX)

A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Obsidian Therapeutics Inc. logo

Obsidian Therapeutics Inc.

NASDAQ:OBXHealthcare
-0.86%$13.86
AH Close$13.86+0.00%vs close
Mkt Cap$856.17M
Float50.01M
O/S61.77M
Inst Own0.0%
SI1.8%
Dilution
Obsidian Therapeutics Inc. logoNASDAQ:OBX$13.86-0.86%
FormDescription
13G
Beneficial Ownership Report
EFFECT
Notice of Effectiveness
S-1
Registration Statement
8-K/A
9.01
10-Q
Quarterly Report
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
S-8
SEC Filing
8-K
1.01,2.01,2.02,3.02,3.03,4.01,5.01,5.02,5.03,7.01,9.01

1-25 of 35